martes, 6 de octubre de 2026
BuscarExplore
Via News Knowledge File

Citigroup Inc.

organization80% conf.·synced Aug 13, 2026

Financial institution hosting Global TMT Conference

55
sourced metrics
298
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Share
58.06USD
May 15, 2026source
Total Notes Outstanding
4750000000USD
Apr 21, 2026source
Investment Banking Revenue
1.33USD
Apr 14, 2026source
Eps
2.64USD
Apr 14, 2026source
Nii Growth
10.7percent
Apr 14, 2026source
Net Interest Income
15.5USD
Apr 14, 2026source
Price Target
331USD
Apr 1, 2026source
Cet1 Ratio
12.7percent
Mar 31, 2026source
Severance Costs
500USD
Mar 31, 2026source
Expense Growth
7percent
Mar 31, 2026source
Share Buybacks
6.3USD
Mar 31, 2026source
Regulatory Capital Requirement
11.6percent
Mar 31, 2026source
Private Credit Exposure
22USD
Mar 31, 2026source
Expenses
14.3USD
Mar 31, 2026source
Reserve To Funded Loans Ratio
2.6percent
Mar 31, 2026source
Cost Of Credit
2.8USD
Mar 31, 2026source
Total Reserves
22USD
Mar 31, 2026source
Acl Build
597USD
Mar 31, 2026source

Stated objectives

NII growth of 5-6% in 2026

source
target: 5-6 percent growth by 2026-01-01 00:00:00stated

NII (excluding Markets) growth

source
target: 5.5% by 2025-01-01 00:00:00stated

Revenue CAGR growth

source
target: 4-5% by 2026-01-01 00:00:00stated

Annualized run rate savings

source
target: $2-2.5 billion by 2026-01-01 00:00:00stated

Return on tangible common equity (RoTCE)

source
target: 10-11% by 2026-01-01 00:00:00stated

Net interest income (excluding markets) growth

source
target: 5-6% year-over-year by 2026-01-01 00:00:00stated

Job cuts

source
target: 20,000 employees (8% of global staff) by 2026-01-01 00:00:00stated

Japan investment banking headcount expansion

source
target: 30% increase stated

Annual revenue growth of 4-5% through 2026

source
target: 4-5% by 2026-12-31 00:00:00stated

Two-year cost-cutting initiative to yield $2-$2.5 billion in annual savings by 2026

source
target: $2-2.5 billion by 2026-12-31 00:00:00stated

Relationship graph · 298 connections

Covered by
82
Employs
63
Competes with
51
subsidiary of
21
regulates
17
rates
10
located in
10
headquartered in
5

Where sources disagree

We surface conflicts between sources rather than hiding them.

value conflictunresolved

Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com